# Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Source: https://onco.cc/trials/nct04626518/  
OnCo record `nct04626518` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Belzutifan, Lenvatinib and Favezelimab in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) is a phase 1/2 interventional study registered as NCT04626518 by Merck Sharp & Dohme LLC, with 370 participants enrolled, started 2020-12-17 and due to reach its primary completion in 2026-08-21. Interventions recorded: Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab and Favezelimab/Pembrolizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04626518
- Phase: 1/2
- Setting: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B in Second-Line Metastatic Participants
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 370

## Sources

- ClinicalTrials.gov NCT04626518: https://clinicaltrials.gov/study/NCT04626518

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Belzutifan](https://onco.cc/drugs/belzutifan/), [Favezelimab](https://onco.cc/drugs/favezelimab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04626518.json